NOV 17, 202656 MINS READ
The earliest documented Creatine Phosphate Phosphorylation Process employed phosphoroxychloride (POCl₃) as the phosphorylating agent, reacting with creatine or creatinine under controlled conditions 1. Zeile and Pawaz (1938) pioneered this approach, achieving phosphorylation by treating creatine with POCl₃ in anhydrous organic solvents such as dichloromethane or 1,2-dichloroethane at temperatures below 105°C 16. The reaction proceeds via formation of N²-dichlorophosphoryl creatinine as an intermediate, which upon hydrolysis with sodium hydroxide yields the disodium salt of phosphocreatine 56. However, this classical route suffers from several critical drawbacks that limit its industrial viability:
Despite these limitations, the chemical route provided foundational insights into the reactivity of creatine's guanidino group and established the feasibility of synthetic phosphocreatine for pharmaceutical applications 15.
A transformative advancement in the Creatine Phosphate Phosphorylation Process emerged with the development of enzymatic synthesis, leveraging creatine kinase (CK, EC 2.7.3.2) to catalyze the reversible transfer of a phosphate group from ATP to creatine 13. The enzymatic route, first adapted from analytical methods by Bergmeyer (1963), was initially deemed impractical for preparative purposes due to the high cost of phosphoenolpyruvate and purified CK 1. However, subsequent innovations demonstrated that crude aqueous muscle extracts containing endogenous CK, combined with 3-phosphoglyceric acid as a low-cost phosphate donor and catalytic amounts of ATP, enable efficient phosphorylation in alkaline media (pH 8.5–10.0) 13.
The enzymatic phosphorylation proceeds via a two-step coupled reaction system:
Phosphoglycerate Kinase (PGK) Reaction:
3-Phosphoglyceric acid + ADP ⇌ 1,3-Bisphosphoglycerate + ATP
(ΔG°' ≈ +18.5 kJ/mol, driven forward by subsequent ATP consumption)
Creatine Kinase Reaction:
Creatine + ATP ⇌ Phosphocreatine + ADP
(ΔG°' ≈ −12.5 kJ/mol under physiological conditions; equilibrium favors phosphocreatine at alkaline pH)
The net reaction is thermodynamically favorable when coupled, with ATP serving as a catalytic intermediate regenerated in situ 1. The use of 3-phosphoglyceric acid circumvents the need for expensive phosphoenolpyruvate, reducing substrate costs by >90% 1. Optimal reaction conditions include:
Yields exceeding 85% have been reported under optimized conditions, with reaction times of 2–6 hours at 30°C 13. The enzymatic process is inherently scalable, as muscle extracts are inexpensive and the reaction can be conducted in standard stirred-tank reactors without the hazards associated with POCl₃ 1.
To further improve economic feasibility, immobilization of creatine kinase on solid supports has been investigated 13. A notable method employs polyvinyl alcohol (PVA) and sodium alginate as gel matrices, entrapping CK within a cross-linked network 13. Key advantages of immobilized CK include:
Immobilization protocols typically involve dissolving 2–5% (w/v) PVA and 1–3% (w/v) sodium alginate in buffer, mixing with CK solution (10–50 U/mL), and cross-linking with glutaraldehyde (0.1–0.5% v/v) or calcium chloride (50–100 mM) to form beads or sheets 13. This technology is particularly suited for continuous or semi-continuous production systems, where enzyme cost constitutes a significant fraction of total manufacturing expenses 13.
Recent patent literature describes a continuous-flow synthesis process for creatine phosphate sodium that addresses key limitations of batch chemical methods 2. This approach integrates micro-channel reactors to achieve precise control over reaction parameters, minimize hazardous reagent inventories, and reduce impurity formation 2. The process comprises the following stages:
Creatinine (dissolved in dichloromethane, 10–20% w/v) and POCl₃ (1.2–1.5 molar equivalents) are fed continuously into a micro-channel reactor (channel diameter 0.5–2 mm, residence time 5–30 seconds) at 60–90°C 2. The high surface-area-to-volume ratio (>10,000 m²/m³) ensures rapid heat transfer and uniform temperature distribution, preventing localized overheating and decomposition 2. The resulting dichlorophosphoric acid creatinine intermediate is concentrated under vacuum (50–100 mbar, 40–60°C) to remove excess POCl₃, then dissolved in toluene and filtered to eliminate residual POCl₃ as a crystalline adduct 2.
The intermediate is transferred to a second micro-channel reactor and reacted with aqueous sodium hydroxide (2.5–3.0 molar equivalents, 15–25% w/v) at 20–40°C (residence time 10–60 seconds) 2. The rapid mixing in micro-channels (mixing time <0.1 seconds) minimizes side reactions such as hydrolysis of the phosphate ester bond, which is a common issue in batch reactors where local pH gradients can exceed pH 13 2. The biphasic mixture is transferred to a phase separator, and the aqueous layer containing creatine phosphate sodium is isolated 2.
The aqueous solution is treated with activated cationic resin (strong acid type, H⁺ form, 5–10% w/v resin loading) under stirring for 30–60 minutes to remove residual inorganic phosphates and metal ion impurities 210. The pH is monitored and adjusted to 9.0–10.0 by controlled addition of NaOH 2. The solution is then filtered through a 0.22 µm microfiltration membrane, and creatine phosphate sodium is crystallized by slow addition of 95% ethanol (2–3 volumes) at 0–10°C 2. The crystalline product is collected by centrifugation, washed with cold ethanol, and dried under vacuum at 40–50°C to yield creatine phosphate sodium tetrahydrate with purity ≥99.5% and yield >40% 210.
Technical Advantages Of Continuous-Flow Process:
An alternative phosphorylation strategy employs protected functional groups to enhance reaction selectivity and minimize N-substituted impurities 411. This approach is particularly relevant for synthesizing creatinol O-phosphate, a structural analog of phosphocreatine with enhanced membrane permeability 411. The process involves:
Creatinol sulfate (1 equivalent) is dissolved in an organic solvent (butanone, ethyl acetate, or acetone, 5–10 volumes) and treated dropwise with concentrated sulfuric acid (1.1–1.3 equivalents) at 0–10°C under vigorous stirring 411. The sulfuric acid protonates the guanidino nitrogen, forming a protected creatinol sulfate intermediate that is stable at room temperature and can be isolated by crystallization 411. This protection step prevents undesired N-phosphorylation during subsequent reaction with POCl₃ or P₂O₅ 411.
The protected creatinol sulfate is reacted with POCl₃ (1.5–2.0 equivalents) or ClPO₃H₂ (1.2–1.5 equivalents) in anhydrous dichloromethane at 40–60°C for 2–4 hours 411. The sulfate protecting group directs phosphorylation exclusively to the hydroxyl oxygen, yielding creatinol O-phosphate dichloride with >95% regioselectivity 411. Hydrolysis with aqueous NaOH (pH 11–12) followed by neutralization affords creatinol O-phosphate disodium salt in 60–75% overall yield 411.
Mechanistic Rationale:
The electron-withdrawing sulfate group reduces the nucleophilicity of the guanidino nitrogen (pKa ~13.5 for free creatinol vs. ~9.0 for sulfate adduct), while the hydroxyl oxygen remains reactive (pKa ~15.5) 411. This pKa differential of >5 units ensures selective O-phosphorylation even in the presence of excess phosphorylating agent 411.
Achieving pharmaceutical-grade purity (≥99.8%) for creatine phosphate sodium requires rigorous removal of inorganic phosphates, unreacted creatine, and trace metal contaminants 1017. Two complementary purification strategies are employed:
The crude creatine phosphate sodium solution (pH 9–10, 5–15% w/v) is pre-treated with 40–70 vol% ethanol to precipitate high-molecular-weight impurities, then loaded onto a strong anion-exchange resin (quaternary ammonium type, Cl⁻ form, bed volume 5–10 column volumes) 10. Elution is performed in a stepwise gradient:
The creatine phosphate-containing fractions are pooled, concentrated under vacuum (40–50°C, 50–100 mbar) to 20–30% w/v, and subjected to crystallization 10.
Ethanol (95%, 2–3 volumes) is added slowly to the concentrated solution at 0–5°C with seeding (0.1–0.5% w/w creatine phosphate sodium crystals) to induce nucleation 210. The slurry is aged for 2–4 hours at 0–5°C, then filtered and washed with cold ethanol 210. Recrystallization from water-ethanol (1:2 v/v) at 10–15°C affords creatine phosphate sodium tetrahydrate with purity ≥99.8%, inorganic phosphate content <0.05%, and creatine content <0.1% 10.
Analytical Validation:
High-performance liquid chromatography with evaporative light-scattering detection (HPLC-ELSD) is employed to quantify impurities 17. A reversed-phase C18 column (250 mm × 4.6 mm, 5 µm) with gradient elution (0.01 M ammonium acetate, pH 6.5, to 50% acetonitrile over 20 minutes) resolves creatine phosphate (retention time ~8.5 min), creatine (~5.2 min), and inorganic phosphates (~3.0 min) with detection limits of 0.01% 17. This method is suitable for in-process monitoring and final product release testing 17.
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| BOEHRINGER MANNHEIM GMBH | Large-scale pharmaceutical production of creatine phosphate where economic feasibility and high yield are critical; suitable for facilities requiring safe, scalable enzymatic synthesis without hazardous phosphoroxychloride. | Enzymatic Phosphocreatine Production System | Achieves excellent yields (>85%) using low-cost 3-phosphoglyceric acid and crude muscle extracts with catalytic ATP, eliminating expensive phosphoenolpyruvate and purified creatine kinase; operates at 25-37°C in alkaline medium (pH 9.0-10.5) with simple heat denaturation (70-100°C) for product isolation. |
| CHONGQING SHENGHUAXI PHARMACEUTICAL CO. LTD. | Industrial pharmaceutical manufacturing requiring enhanced safety (reduced explosion/toxicity risks), high product purity (≥99.5%), and scalable throughput via numbering-up of parallel micro-channels for creatine phosphate sodium production. | Continuous-Flow Creatine Phosphate Sodium Synthesis | Micro-channel reactors (0.5-2 mm diameter, residence time 5-60 seconds) reduce POCl₃ inventory to <100 mL (vs. 10-50 L batch), achieving >99.5% purity and >40% yield; suppresses N-substituted impurities to <0.5% (vs. 3-5% batch) through precise temperature control and rapid mixing (<0.1 seconds). |
| TIANJIN TIANCHENG PHARMACEUTICAL CO. LTD. | Pharmaceutical synthesis of creatinol O-phosphate analogs with enhanced membrane permeability for cardioprotective and muscle energy applications; suitable for processes requiring high selectivity and minimal impurity formation. | Protected Creatinol O-Phosphate Synthesis Process | Sulfate-protected functional group strategy achieves >95% regioselectivity for O-phosphorylation, yielding creatinol O-phosphate disodium salt in 60-75% overall yield; reduces N-substituted impurities by directing phosphorylation exclusively to hydroxyl oxygen via pKa differential (>5 units). |
| 西南药业股份有限公司 | Final purification stage in creatine phosphate sodium manufacturing for injectable pharmaceutical products requiring stringent quality control; applicable to facilities with HPLC-ELSD analytical validation capabilities. | Ion-Exchange Purification for Pharmaceutical-Grade Creatine Phosphate | Strong anion-exchange chromatography with stepwise NaCl gradient (0.02-0.8 M) achieves ≥99.8% purity, <0.05% inorganic phosphate, and <0.1% creatine content; combined with ethanol crystallization (2-3 volumes at 0-5°C) yields creatine phosphate sodium tetrahydrate meeting pharmaceutical standards. |
| HANGZHOU TSINGHKE BIOLOGICAL SCIENCE AND TECHNOLOGY CO. LTD. | Continuous or semi-continuous enzymatic phosphocreatine production systems where enzyme cost is significant; suitable for industrial bioreactors requiring enhanced enzyme reusability and simplified downstream processing. | Immobilized Creatine Kinase System | PVA-sodium alginate gel matrix immobilization retains >70% CK activity after 10 cycles (vs. <5% free enzyme), extends operational half-life from ~8 hours to >50 hours, and enables enzyme recovery by filtration, reducing protein contamination and heat denaturation requirements. |